Brailo V, Vucicevic-Boras V, Lukac J, Biocina-Lukenda D, Zilic-Alajbeg I, Milenovic A, Balija M. Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal. 2012 Jan 1;17 (1):e10-5.

doi:10.4317/medoral.17323

http://dx.doi.org/doi:10.4317/medoral.17323

1. Axéll T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996;25:49-54.
http://dx.doi.org/10.1111/j.1600-0714.1996.tb00191.x
PMid:8667255

2. Van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45:317-23.
http://dx.doi.org/10.1016/j.oraloncology.2008.05.016
PMid:18674954

3. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol.2006;42:461-74.
http://dx.doi.org/10.1016/j.oraloncology.2005.08.011
PMid:16316774

4. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-basedpopulation of 166 patients with oral leukoplakia from The Netherlands. OralOncol. 1998;34:270-5.
PMid:9813722

5. Van der Waal I, Schepman KP, van der Meij EH, Smeele LE. Oral leukoplakia: a clinicopathological review. Oral Oncol. 1997;33:291-301.
http://dx.doi.org/10.1016/S1368-8375(97)00002-X

6. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-147.
PMid:8630372

7. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, et al. Effects of micro environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer. 2006;42:751-9.
http://dx.doi.org/10.1016/j.ejca.2006.01.010
PMid:16530403

8. Oyama N, Iwatsuki K, Homma Y, Kaneko F. Induction of transcription factor AP-2 by inflammatory cytokines in human keratinocytes. J Invest Dermatol. 1999;113:600-6.
http://dx.doi.org/10.1046/j.1523-1747.1999.00734.x
PMid:10504447

9. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005;65:4673-82.
http://dx.doi.org/10.1158/0008-5472.CAN-04-3589
PMid:15930285

10. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35-53.
http://dx.doi.org/10.1016/j.cytogfr.2004.11.001

11. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, et al. Tumor necrosis factor alpha is a potent endogenous mutagen that promotes cellulartransformation. Cancer Res. 2006;66:11565-70.
http://dx.doi.org/10.1158/0008-5472.CAN-06-2540
PMid:17178846

12. Brill AH. The TNM system for clinical staging of oral malignant tumors.Otolaryngol Clin North Am. 1979;12:69-71.
PMid:440749

13. Wu-Wang CY, Patel M, Feng J, Milles M, Wang SL. Decreased levels of salivary prostaglandin E2 and epidermal growth factor in recurrent aphthous stomatitis. Arch Oral Biol. 1995;40:1093-8.
http://dx.doi.org/10.1016/0003-9969(95)00095-X

14. Ainamo J, Barmes D, Beagrie G, Cutress T, Martin J, Sardo-Infirri J. Development of the World Health Organization (WHO) community periodontal index of treatment needs (CPITN). Int Dent J. 1982;32:281-91.
PMid:6958657

15. Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, et al. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2008;14:705-12.
http://dx.doi.org/10.1111/j.1601-0825.2008.01488.x
PMid:19193200    PMCid:2675698

16. Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K, et al. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2007;48:199-203.
http://dx.doi.org/10.2209/tdcpublication.48.199
PMid:18360107

17. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol. 2005;114:278-83.
http://dx.doi.org/10.1016/j.clim.2004.12.003
PMid:15721838

18. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005;44:77-82.
http://dx.doi.org/10.1002/mc.20113
PMid:16075467

19. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A. Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008;13:E292-5.
PMid:18449112

20. Vucicević Boras V, Cikes N, Lukać J, Virag M, Cekić-Arambasin A. Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol. 2005;54:569-73.
PMid:16224376

21. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:929-35.
http://dx.doi.org/10.1001/archotol.130.8.929
PMid:15313862

22. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999;5:1369-79.
PMid:10389921

23. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev. 2008;17:3450-6.
http://dx.doi.org/10.1158/1055-9965.EPI-08-0311

24. Jablonska E, Piotrowski L, Grabowska Z. Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer. Pathol Oncol Res. 1997;3:126-129.
http://dx.doi.org/10.1007/BF02907807

25. Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM,et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope. 2005;115:522-7.
http://dx.doi.org/10.1097/01.mlg.0000157850.16649.b8
PMid:15744170

26. Hoffmann TK, Sonkoly E, Homey B, Scheckenbach K, Gwosdz C, Bas M, et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck. 2007;29:472-8.
http://dx.doi.org/10.1002/hed.20533

27. Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol. 2008;79:1913-9.
http://dx.doi.org/10.1902/jop.2008.080070
PMid:18834246

28. Miller CS, King CP Jr, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: a cross-sectional study. J Am Dent Assoc. 2006;137:322-9.
PMid:16570465

29. Brailo V, Vucićević-Boras V, Cekić-Arambasin A, Alajbeg IZ, Milenović A, Lukac J. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia.Oral Oncol. 2006;42:370-3.
http://dx.doi.org/10.1016/j.oraloncology.2005.09.001
PMid:16324876

30. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006;17:141-6.
http://dx.doi.org/10.1016/j.cytogfr.2006.02.001